Itraconazole - Mayne Pharma

Drug Profile

Itraconazole - Mayne Pharma

Alternative Names: Itragerm; Itraisdin; Lozanoc; Mytra; SUBA; SUBA®-itraconazole; Subacap

Latest Information Update: 23 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mayne Pharma Group
  • Developer HedgePath Pharmaceuticals; Mayne Pharma Group
  • Class Antifungals; Antineoplastics; Azoles; Chlorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Basal cell cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Mycoses

Highest Development Phases

  • Marketed Mycoses
  • Phase II Basal cell cancer

Most Recent Events

  • 09 Oct 2018 HedgePath Pharmaceuticals is planning to file NDA with the US FDA for basal cell carcinoma nevus syndrome (BCCNS) in first half of 2019
  • 19 Jul 2018 HedgePath Pharmaceuticals and University of Connecticut enter into exclusive option license agreement for patents and patent applications covering chemical analogues of itraconazole
  • 05 Jun 2018 Updated efficacy and adverse events data from a phase IIb trial in Basal cell cancer released by HedgePath Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top